LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
-8.08%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$282M
AUM Growth
+$282M
(+1.8%)
Cap. Flow
+$38.6M
Cap. Flow
% of AUM
13.69%
Top 10 Holdings %
Top 10 Hldgs %
99.23%
Holding
21
New
4
Increased
7
Reduced
3
Closed
3
Top Buys
| 1 |
Merus
MRUS
|
$29.3M |
| 2 |
Allogene Therapeutics
ALLO
|
$11.1M |
| 3 |
Passage Bio
PASG
|
$2.36M |
| 4 |
GH Research
GHRS
|
$1.53M |
| 5 |
Caribou Biosciences
CRBU
|
$1.33M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$4.52M |
| 2 |
Cabaletta Bio
CABA
|
$3.68M |
| 3 |
Korro Bio
KRRO
|
$129K |
| 4 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$101K |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
$31.7K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $89.6M | 31.75% | 1,793,866 +587,159 | +49% | +$29.3M |
|
2
Stoke Therapeutics
STOK
$1.08B
| $63.8M | 22.59% | 5,187,191 +2,000 | +0% | +$24.6K |
|
3
C4 Therapeutics
CCCC
$185M
| $39.2M | 13.9% | 6,880,527 | – | – |
|
|
4
GH Research
GHRS
$837M
| $28.1M | 9.95% | 4,195,894 +229,168 | +6% | +$1.53M |
|
5
TScan Therapeutics
TCRX
$102M
| $26M | 9.22% | 5,224,600 | – | – |
|
|
6
Allogene Therapeutics
ALLO
$251M
| $17.4M | 6.15% | 6,202,374 +3,974,079 | +178% | +$11.1M |
|
7
Cullinan Oncology
CGEM
$445M
| $6.88M | 2.44% | 410,830 +33,507 | +9% | +$561K |
|
|
8
Passage Bio
PASG
$22.7M
| $5.9M | 2.09% | 8,426,955 +3,369,326 | +67% | +$2.36M |
|
9
iBio
IBIO
$16.1M
| $1.91M | 0.68% | 862,279 +21,516 | +3% | +$47.8K |
|
|
10
Caribou Biosciences
CRBU
$174M
| $1.33M | 0.47% | +680,189 | New | +$1.33M |
|
11
Kodiak Sciences
KOD
$478M
| $708K | 0.25% | +271,177 | New | +$708K |
|
|
PVLA
12
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $621K | 0.22% | 37,436 -6,063 | -14% | -$101K |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $278K | 0.1% | 17,400 | – | – |
|
|
NEUP
14
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $241K | 0.09% | 549,673 -50,000 | -8% | -$22K |
|
|
15
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $206K | 0.07% | 8,231 -1,269 | -13% | -$31.7K |
|
16
Tenax Therapeutics
TENX
$27.3M
| $51K | 0.02% | +14,751 | New | +$51K |
|
17
Century Therapeutics
IPSC
$42.5M
| $32.5K | 0.01% | +19,028 | New | +$32.5K |
|
18
VYNE Therapeutics
VYNE
$8.16M
| $30.4K | 0.01% | 16,194 | – | – |
|
|
19
Cabaletta Bio
CABA
$133M
| – | – | -492,103 | Closed | -$3.68M |
|
|
20
Korro Bio
KRRO
$217M
| – | – | -3,800 | Closed | -$129K |
|
|
LBPH
21
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – | -167,317 | Closed | -$4.52M |
|